# An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites

> **NCT01330472** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Xanax XR tablets 3 mg (sourced from Caugus)
- **DRUG:** Xanax XR tablets 3 mg (sourced from Barceloneta)

## Key facts

- **NCT ID:** NCT01330472
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01330472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01330472, "An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01330472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*